Skip to main content

Bio-Path Holdings(BPTH-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Bio-Path Holdings

4710 BELLAIRE BOULEVARD SUITE 210
BELLAIRE TX 77401 USA
P: 832-742-1357
http://www.biopathholdings.com

Profile

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.

Key Executives

NameTitle
Peter H. NielsenCEO/CFO/Chairman of the Board/Chief Accounting Officer/Co-Founder/Director/President/Treasurer
Douglas P. MorrisCo-Founder/Director/Other Corporate Officer/Secretary

More from The Globe